HealthcareServices

Influenza Diagnostic Sector Forecast Shows Robust Momentum, Climbing to $4.18 Billion With 7.8% CAGR

February 25, 2026February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the influenza diagnostic market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Influenza Diagnostic Market between 2026 and 2030?

The influenza diagnostic market has experienced substantial growth recently. It is projected to expand from $2.87 billion in 2025 to $3.1 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.3%. Historically, this expansion has been driven by factors such as seasonal influenza outbreaks, the widespread adoption of rapid antigen tests, the development of hospital laboratory infrastructure, governmental influenza surveillance initiatives, and heightened awareness regarding early flu diagnosis.

The influenza diagnostic market is anticipated to experience robust expansion over the coming years. This market is projected to reach $4.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth during the projection period include an increasing incidence of influenza epidemics, the escalating need for precise molecular diagnostics, the proliferation of point-of-care testing sites, heightened public health readiness efforts, and innovations in rapid diagnostic assay technologies. Key trends observed during this period are the surging requirement for quick influenza tests, wider acceptance of molecular diagnostic techniques, a developing preference for point-of-care flu diagnostic solutions, the broadening scope of seasonal and pandemic surveillance testing, and ongoing enhancements in test sensitivity and specificity.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3237&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Influenza Diagnostic Market?

Expanding financial investment into influenza diagnostics research is projected to advance the expansion of the influenza diagnostic market moving ahead. This funding encompasses monetary allocations from governmental bodies, institutions, and various organizations, purposed to back scientific inquiries focused on innovating, refining, and confirming techniques and technologies for identifying and detecting influenza viruses. The uptick in funding for influenza studies stems from insights gained during the COVID-19 pandemic and worries about potential future respiratory disease epidemics, as health authorities acknowledge the vital necessity of swift and precise diagnostic tools to avert extensive spread and facilitate prompt public health actions. Enhanced research investment aids in the creation and market introduction of sophisticated testing methods, molecular analyses, rapid point-of-care devices, and refined laboratory protocols, all of which allow for quicker and more precise identification of influenza strains within clinical environments. For example, in October 2024, as reported by the Department of Health and Aged Care, a government entity in Australia overseeing health research, funding, promotion, and regulation, the Australian Government is committing $95 million to address avian influenza, thereby safeguarding agriculture, wildlife, and the economy. Consequently, the increased financial support for influenza diagnostics research is fueling the expansion of the influenza diagnostic market.

What Segments Are Included Within The Influenza Diagnostic Market?

The influenza diagnostic market covered in this report is segmented –

1) By Traditional Diagnostic Tests: Rapid Influenza Diagnostic Tests (RIDT), Viral Culture, DFA, Serological Assays, Other Traditional Diagnostic Tests

2) By Molecular Diagnostic Tests: Reverse Transcription Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification Tests (INAAT), Loop Mediated Isothermal Based Amplification Assays, Transcription Mediated Isothermal Based Amplification Assays, Other Isothermal Nucleic Acid Amplification Tests, Other Molecular Diagnostic Tests

3) By End User: Hospitals And Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Other End Users

Subsegments:

1) By Rapid Influenza Diagnostic Tests (RIDT): Immunoassay-based Tests, Lateral Flow Assays, Enzyme Immunoassays (EIA)

2) By Viral Culture: Cell Culture, Egg-based Culture

3) By Serological Assays: Hemagglutination Inhibition (HI) Assay, Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting Assay

4) By Other Traditional Diagnostic Tests: Polymerase Chain Reaction (PCR), Immunofluorescence Assays

How Are New Market Trends Shaping The Landscape Of The Influenza Diagnostic Market?

Companies operating within the influenza diagnostic market are actively developing innovative products, such as the Lucira COVID-19 & Flu Home Test, intended for the rapid and simultaneous qualitative detection of multiple viruses. The Lucira COVID-19 and Flu Home Test is designed as a single-use kit for at-home use, providing results from self-collected nasal swab samples in approximately 30 minutes. For example, in February 2023, Pfizer Inc., a US-based pharmaceutical company, secured approval for the Lucira COVID-19 & Flu Home Test. This diagnostic tool is capable of identifying influenza A and B, commonly known as the flu, as well as SARS-CoV-2, the virus responsible for COVID-19.

Who Are The Major Companies Operating In The Influenza Diagnostic Market?

Major companies operating in the influenza diagnostic market are F. Hoffmann-La Roche Ltd., Quidel Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Hologic Inc., Becton Dickinson and Company, DiaSorin SpA, Luminex Corporation, Meridian Bioscience Inc., GenMark Diagnostics Inc., SA Scientific Ltd., Sekisui Diagnostics LLC, bioMérieux Inc., Danaher Corporation, Siemens Healthineers AG, Coris Bioconcept Sprl, Mast Group, Elitech Technology lnc., Analytik Jena AG, altona Diagnostics GmbH, Tecan Trading AG, Genome Diagnostics Pvt Ltd., Germaine Laboratories Inc., Response Biomedical Corporation, TAUNS Laboratories Inc., TRUPCR Europe Ltd., Quest Diagnostics Inc., Labcorp Employer Services Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Influenza Diagnostic Market?

North America was the largest region in the influenza diagnostics market in 2025. Western Europe was the second largest region in the influenza diagnostics market. The regions covered in the influenza diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Influenza Diagnostic Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3237&type=smp

Browse Through More Reports Similar to the Global Influenza Diagnostic Market 2026, By The Business Research Company

Infectious Disease Diagnostics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/infectious-disease-diagnostics-testing-global-market-report

Influenza Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Influenza Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795